Editorial Commentary
FOCUS trial: results, potentialities and limits
Abstract
In January 2019 Lancet has published the paper “Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial” (1). The main purpose of this prospective trial was to asses if fluoxetine [a selective serotonin reuptake inhibitor (SSRI) drug] could improve recovery after stroke.
